Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154

ClinicalTrials.gov ID: NCT04972968

Public ClinicalTrials.gov record NCT04972968. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 11, 2026, 12:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Polymyalgia rheumatica (PMR) is an inflammatory disease causing shoulder, hip, and neck pain and stiffness, in adults aged 50 years or older. This study evaluates how safe and effective ABBV-154 is in participants with glucocorticoid-dependent PMR. Adverse events and change in disease activity will be assessed. ABBV-154 is an investigational drug being evaluated for the treatment of PMR. Participants will be randomized into 1 of 4 treatment groups or arms, each arm receiving a different treatment. There is a 1 in 4 chance that a participant will be assigned to placebo. Around 160 participants, of at least 50 years of age, with PMR will be enrolled in the study at approximately 95 sites worldwide. The study is compromised of a 52 week double-blind, placebo-controlled period and a follow-up visit 70 days after the last dose of the study drug. All participants will receive a glucocorticoid taper along with the assigned dose of ABBV-154 or placebo, subcutaneously (SC) every other week (eow). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Study identification

NCT ID
NCT04972968
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
AbbVie
Industry
Enrollment
181 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
50 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 8, 2021
Primary completion
Jul 23, 2023
Completion
Jul 23, 2023
Last update posted
Oct 14, 2024

2021 – 2023

United States locations

U.S. sites
31
U.S. states
16
U.S. cities
31
Facility City State ZIP Site status
Arthritis and Rheumatism Associates /ID# 232089 Jonesboro Arkansas 72401-6251
Providence Medical Foundation /ID# 228681 Fullerton California 92835
Care Access Research, Huntington Beach /ID# 228677 Huntington Beach California 92648
Purushotham & Akther Kotha MD, Inc /ID# 245391 La Mesa California 91942
Arthritis & Osteo Medical Ctr /ID# 228680 La Palma California 90623-1728
Hans Richard Barthel, M.D., Inc /ID# 231902 Santa Barbara California 93108
Medvin Clinical Research /ID# 228675 Tujunga California 91042-2706
Inland Rheum & Osteo Med Grp /ID# 228679 Upland California 91786
Denver Arthritis Clinic /ID# 245736 Denver Colorado 80230
Delaware Arthritis /ID# 230110 Lewes Delaware 19958
Arthritis & Rheumatic Disease Specialties /ID# 245448 Aventura Florida 33180
Rheumatology Associates of South Florida (RASF) - Clinical Research /ID# 232238 Boca Raton Florida 33486
International Medical Research /ID# 228765 Daytona Beach Florida 32117
Omega Research Debary, LLC /ID# 245450 DeBary Florida 32713-2260
Lakes Research, LLC /ID# 228757 Miami Florida 33014
HMD Research LLC /ID# 228767 Orlando Florida 32819
Springfield Clinic /ID# 228840 Springfield Illinois 62702-3749
Four Rivers Clinical Research /ID# 228858 Paducah Kentucky 42001
Rheumatology Consultants - Clinical Research /ID# 232137 Tupelo Mississippi 38801-4949
Dartmouth-Hitchcock Medical Center /ID# 229557 Lebanon New Hampshire 03756
Ocean Rheumatology, PA /ID# 232539 Toms River New Jersey 08755
Hospital for Special Surgery /ID# 228577 New York New York 10021
St. Lawrence Health System /ID# 229702 Potsdam New York 13676
University of Rochester Medical Center /ID# 232554 Rochester New York 14642
Paramount Medical Research Con /ID# 228839 Middleburg Heights Ohio 44130
Clinical Research Source, Inc. /ID# 231903 Perrysburg Ohio 43551
Altoona Ctr Clinical Res /ID# 232493 Duncansville Pennsylvania 16635
Articularis Healthcare Group, Inc d/b/a Low Country Rheumatology /ID# 228860 Summerville South Carolina 29486-7887
West Tennessee Research Institute /ID# 228854 Jackson Tennessee 38305
Rheumatology Care Center PLLC /ID# 232306 Bellaire Texas 77401-2900
DM Clinical Research - Tomball /ID# 245512 Tomball Texas 77375

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 86 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04972968, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 14, 2024 · Synced Sep 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04972968 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →